Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Serum interleukin-2 levels in a patient with focal segmental glomerulosclerosis

Relationship to clinical course and cyclosporin A therapy

  • 22 Accesses

  • 17 Citations

Abstract

We describe a patient with steroid-resistant focal segmental glomerulosclerosis (FSGS) whose serum interleukin-2 (IL-2) levels were markedly elevated in association with disease activity. With cyclosporin A (CsA) treatment, the patient entered remission and serum IL-2 fell to undetectable levels. After cessation of CsA, the patient relapsed and the serum IL-2 levels were elevated again. Reinstitution of CsA therapy was followed by a partial remission and disappearance of detectable serum IL-2 levels.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Meyrier A, Simon P, Perret G, Condamin MC (1986) Remission of idiopathic nephrotic syndrome after treatment with cyclosporin A. Br Med J 292:789–792

  2. 2.

    Tejani A, Butt K, Trachtman H, Suthanthiran M, Rosenthal C, Khawar MR (1987) Cyclosporin-induced remission of relapsing nephrotic syndrome in children. J Pediatr 111:1056–1061

  3. 3.

    Waldo R, Kohaut E (1987) Therapy of focal segmental glomerulosclerosis with cyclosporin A. Pediatr Nephrol 1: 180–182

  4. 4.

    Niaudet P, Habib R, Tete M-J, Hinglas N, Broyer M (1987) Cyclosporin in the treatment of idiopathic nephrotic syndrome in children. Pediatr Nephrol 1:566–573

  5. 5.

    Schnaper HW, Aunne TM (1985) Identification of the lymphokine soluble immune response suppressor in urine of nephrotic children. J Clin Invest 76:341–349

  6. 6.

    Tejani A, Khalid B, Trachtman H, Suthanthiran M, Rosenthal C, Khawm M (1988) Cyclosporin A induced remission of relapsing nephrotic syndrome in children Kidney Int 33:729–734

  7. 7.

    Barnett HL, Schoeneman M, Bernstein J, Edelmann CM (1978) Pediatric kidney diseases. Little Brown & Co, Boston, pp 695–711

  8. 8.

    Wiesinger D, Borel JF (1979) Studies on the mechanisms of action of cyclosporin A. Br J Pharmacol 66:66–67

  9. 9.

    Bunjes D, Hardt C, Solbach W (1982) Studies on the mechanism of action of cyclosporin A in the murine and human T-cell response in vitro. In: White DJG (ed) Cyclosporin A. Proceedings of the International Congress on Cyclosporin A. Elsevier Amsterdam, pp 261–280

  10. 10.

    Abb J, Abb H (1983) Effect of cyclosporine on human leukocyte interferon production: selective inhibition of IFN-gamma synthesis. Transplant Proc 15:2380–2383

  11. 11.

    Textor SC, Margolin K, Blayney D, Carlson J, Doroshow J (1987) Renal, volume and hormonal changes during therapeutic administration of recombinant interleukin-2 in man. Am J Med 83:1055–1061

  12. 12.

    Cornaby A, Simpson M, Vann Rice R, Dempsey RA, Madras PN, Monaco AP (1988) Interleukin-2 production in plasma and urine, plasma interleukin-2 receptor level, and urine cytology as a means of monitoring renal allograft recipients. Transplant Proc 20:108–110

Download references

Author information

Correspondence to Stanley C. Jordan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jordan, S.C., Querfeld, U., Toyoda, M. et al. Serum interleukin-2 levels in a patient with focal segmental glomerulosclerosis. Pediatr Nephrol 4, 166–168 (1990). https://doi.org/10.1007/BF00858831

Download citation

Key words

  • Interleukin-2
  • Focal segmental glomerulosclerosis
  • Cyclosporin A